目的 探讨以环氧合酶-2(COX-2)为靶点治疗慢性乙型肝炎肝纤维化的临床疗效.方法 慢性乙型肝炎肝纤维化藏族患者47例随机分为2组,对照组给予护肝片,治疗组给予COX-2抑制剂塞来昔布,疗程均为24周.观察2组患者血清III型前胶原纤维(PCIII)、IV胶原纤维(CIV)、透明质酸(HA)、层黏连蛋白(LN)及肝病理学变化.结果 治疗组治疗后血清PCIII、CIV、HA、LN水平较治疗前及对照组明显下降(P＜0.05);肝纤维化改善率优于对照组(90.6% vs 13.3%,P<0.05).结论 以COX-2为靶点治疗能改善慢性乙型肝炎肝纤维化进程,可成为抗肝纤维化的一项新型措施.%Objective To analyze the therapeutic effect of chronic hepatitis B hepatic fibrosis by the target point of cyclooxygenase 2( COX-2 ). Methods A total of 47 Tibetan nationality patients with chronic hepatitis B hepatic fibrosis were randomly divided into two groups. The patients in the control group were treated with Hugan tablet, the patients in the treatment group received celecoxib, The pro collagen fiber Ⅲ, collagen fiber Ⅳ, hyaluronic acid, laminin in serum were observed and compared liver pathology, s diversity between the two groups. Results The pro collagen fiber Ⅲ,collagen fiber Ⅳ, hyalu-ronic acid, laminin returned to normal faster before treatment in the treatment group and that in the control group ( P < 0.05 ). After 24 weeks of treatment the improvement in the liver pathology,s diversity was superior to that in the control group ( P < 0. 05 ). Conclusion To treat by the target point of cyclooxygenase-2 can relieve the processes of chronic hepatitis B hepatic fibrosis and it is a new therapeutic measure.
展开▼
